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 Congenital and infantile malignant melanomas are rare.
 Surgery is the mainstay of treatment.
 Prognosis of the condition remains poor.
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a b s t r a c t
Congenital and infantile malignant melanomas are rare and typically carry poor prognosis. The purpose
of this article was to review the data on congenital and infantile malignant melanomas of the scalp in
order to understand its presentation, diagnosis, management, and outcomes of congenital melanoma of
scalp. We searched PubMed, CINAHL and Cochrane databases. Ten cases of congenital and 3 cases of
infantile malignant melanoma of scalp were identiﬁed. The diagnosis was conﬁrmed by biopsy and
histological analysis for conﬁrmation. The prognosis depends on the origin of disease (congenital mel-
anocytic nevus, transplacental metastasis, or de-novo), tumor thickness, the presence of ulceration and/
or necrosis, and anatomic site (scalp lesions having poor prognosis). The most commonly used treatment
of the reported cases of congenital and infantile melanoma was surgical excision of the primary lesion.
Further modes of treatment may be extrapolated from the treatment of childhood and adult melanomas.
© 2017 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Malignant melanoma is a neoplasm arising from the melano-
cytes. Melanocytes are predominantly found in the basal layer of
the skin epidermis (at the junction of epidermis and dermis). They
are also found in the uvea of the eye, meninges, and ectodermal
mucosa. The average age at diagnosis of melanoma is 57 years and
is more common in men [1].
Melanoma in the children accounts for 1%e4% of all cases of
melanoma, and 1%e3% of all pediatric malignancies [2]. Pediatric
melanoma can be divided into four categories based on the age of
occurrence: congenital (in utero to birth), infantile (from birth to 1
year), childhood (1 year to puberty) and adolescent melanoma
(puberty to 21 years) [3]. Congenital and infantile malignant mel-
anomas are the least common variety of pediatric melanomas. Only
36 cases of congenital and infantile melanomas have been reported
in literature since 1925 [4e12].
Congenital or infantile Malignant melanomas are further
grouped into three categories based on the origin of the disease: 1)
arising within congenital melanocytic nevus (benign proliferation
of melanocytes), 2) arising de-novo (from non-lesional skin) and 3)
from transplacental metastasis (from maternal lesions) [13]. The
purpose of this this article was to review the data on congenital and
infantile malignant melanomas of the scalp in order to understand
its presentation, diagnosis, management and outcomes.
2. Methods
We searched PubMed, CINAHL and Cochrane databases for ar-
ticles on congenital or infantile malignant melanoma of scalp.
Search strategy was to use MeSH terms of [Malignant melanoma]
and [Scalp]. The search was further reﬁned by using [infants] or
[infant] or [Congenital]. The search was run on 13th April 2016 and
repeated on 10th May 2016 by two authors independently. We
included all the studies on malignant melanoma of scalp irre-
spective of study design and date of publication. Selected studies
were critically reviewed for a descriptive review. We followed
PRISMA guidelines [14] for reporting of the review which was
registered with research registry UIN: www.researchregistry.com.
3. Results and discussion
3.1. Epidemiology of congenital or infantile malignant melanoma of
the scalp
Our literature search revealed 10 cases of congenital
[7e9,11,15e19], and 3 cases of infantile [13,20,21] malignant mel-
anoma that were located on the scalp. Six of the 10 congenital scalp
melanoma cases and one case of infantile melanoma arose from
congenital melanocytic nevi, whereas remaining cases were de-
novo in origin. Eight patients were male while ﬁve were female.
Previous literature supports this male preponderance [13] and is
consistent among different age groups [22].
3.2. Diagnosis
Diagnosis of malignant melanoma presents is a challenge. Bi-
opsy is essential to establish a deﬁnitive diagnosis. The histological
characteristics of melanoma include pagetoid intraepidermal
spread, absence of maturation, increased cellularity and/or dermal
mitotic ﬁgures [23]. No single histologic characteristic is diagnostic
of melanoma. Rather it is the aggregation of histological features,
which directs the diagnosis for or against melanoma [23]. Amongst
the immunohistochemical markers of malignant melanoma, S-100
remains the most sensitive marker. However, the speciﬁcity of S-
100 is limited [24]. More speciﬁc markers like HMB-45, Melan-A or
tyrosinase are used in conjunction with S-100 [24]. Another typical
ﬁnding of cutaneous melanomas is that the direct invasion of bone
is exceedingly rare [25].
3.3. Prognosis and outcomes of congenital or infantile malignant
melanoma of the scalp
Outcomes of malignant melanoma of scalp are generally
unfavourable. Of the thirteen reported cases, 6 expired within 6
months of age [4,7,8,11], 1 was lost to follow-up and remaining
were alive at least till the last follow-up [4,9].
Itwasbelieved thatmelanoma in children carry a better prognosis
compared to adults, probably because of misdiagnosis of relatively
benign conditions like spitz nevi as malignant melanomas [6,26].
However, it is now seen that prognosis depends on a number of fac-
tors. The origin of the disease is an important factor in determining
prognosis. Transplacentally acquired melanomas fare the worst
prognosis; in 3 out of 4 such reported cases,multi organ involvement
(particularly of the liver) was noted, and death occurred within the
ﬁrst year of life [4,13]. Melanomas arising from a giant congenital
melanocytic nevus tend to develop deep in the dermis or subcu-
taneous tissue; therefore, malignant melanoma are diagnosed at an
advanced stage [4]. Melanomas arising de-novo appear to have a
better prognosis and life expectancy than the former two; according
to Asai et al. Two of the 12 patients with de-novo congenital and in-
fantilemelanoma expired in infancy [4]. Recent reports by Enamet al.
and Sue et al. bring that count up to 4 [7,11].
According to Balch et al., tumor thickness and ulceration are the
most important prognostic factors in patients with localized mel-
anoma (stage 1 and 2) [27]. Ulceration (deﬁned as absence of
epidermis above the tumor) is a result of the primary melanoma
invading the overlying epidermis instead of displacing it. Hence, an
ulcerated melanoma has a greater metastatic capacity than its non-
ulcerated counterpart of equal thickness [27]. The presence of tu-
mor necrosis in a cutaneous melanoma is also an indicator of poor
patient survival. The frequency of necrosis and its signiﬁcance as a
prognostic factor increases with tumor thickness [28]. Tumor ne-
crosis was seen in5, and ulcerationwas seen in 6 cases of congenital
and infantile malignant melanoma [7e9,11,17]; all patients with
tumor necrosis had a poor prognosis.
The anatomic site of the primary melanoma also plays a role in
determining the prognosis. Melanomas of scalp and neck had a
particularlypoorprognosis [27]. Themost commonsite forcongenital
and infantile melanoma is also the head and neck region [9]. Ac-
cording to one study, scalp andneckmelanomas account for about 6%
of all melanomas but are responsible for 10% of all melanoma related
deaths [29]. As compared to other anatomic locations, scalp mela-
nomas are also more likely to metastasize to regional lymph nodes
andbeulcerated [29]. The reasonbehind thisworseprognosis of scalp
and neck melanomas is not clear. A possibility could be that sentinel
lymph node1 (SLN) biopsy for the head and neck present with a
number of challenges, which may inﬂuence the accuracy of the pro-
cedure [30]. These false negative SLN biopsies can lead to recurrences
of melanoma. Nevertheless, such conclusions are difﬁcult to bemade
for congenital melanoma due to the rarity of reported cases.
3.4. Treatment of congenital or infantile malignant melanoma of
the scalp
Most of the congenital and infantile melanoma underwent
1 Sentinel lymph node is deﬁned as a node that receives direct independent
drainage from the primary melanoma site.
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surgical excision. Other modalities of treatment like interferon-a
have been used more commonly in adults and children.
Role of SLN biopsies in congenital and infantile scalpmelanomas
is not well established. However, a recent study found it useful in
the treatment of childhoodmelanoma [31]. The pathologic result of
SLN biopsy in the most important prognostic factor for recurrence
in cutaneous melanomas [32]. SLN biopsy is also useful in selecting
patients who are most likely to beneﬁt from complete lymph node
dissection and other possible adjuvant therapy. The role of Inter-
feron-a for congenital melanoma is limited because it can be
associated with severe morbidity in neonates [6], even though it is
currently the most widely used adjuvant treatment for melanoma
in other age groups [32].
4. Conclusion
Congenital and infantile malignant melanoma of the scalp are
rare, and difﬁcult to diagnose without biopsy and histological
analysis. These lesions carry poor prognosis. Bad prognostic factors
include location, origin of disease, thickness, ulceration and/or
necrosis of the lesion. Surgical excision remains the primary
treatment modality.
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